- Home
- DMAC vs SLN Comparison
DMAC vs SLN Comparison
Compare DMAC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- SLN
- Stock Information
- Founded
- DMAC 2000
- SLN 1994
- Country
- DMAC United States
- SLN United Kingdom
- Employees
- DMAC N/A
- SLN N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- SLN Health Care
- Exchange
- DMAC Nasdaq
- SLN Nasdaq
- Market Cap
- DMAC 310.1M
- SLN 299.4M
- IPO Year
- DMAC N/A
- SLN N/A
- Fundamental
- Price
- DMAC $5.98
- SLN $5.20
- Analyst Decision
- DMAC Strong Buy
- SLN Buy
- Analyst Count
- DMAC 3
- SLN 5
- Target Price
- DMAC $12.33
- SLN $32.60
- AVG Volume (30 Days)
- DMAC 314.0K
- SLN 65.3K
- Earning Date
- DMAC 08-12-2025
- SLN 08-07-2025
- Dividend Yield
- DMAC N/A
- SLN N/A
- EPS Growth
- DMAC N/A
- SLN N/A
- EPS
- DMAC N/A
- SLN N/A
- Revenue
- DMAC N/A
- SLN $27,169,000.00
- Revenue This Year
- DMAC N/A
- SLN N/A
- Revenue Next Year
- DMAC N/A
- SLN N/A
- P/E Ratio
- DMAC N/A
- SLN N/A
- Revenue Growth
- DMAC N/A
- SLN 22.28
- 52 Week Low
- DMAC $3.19
- SLN $1.97
- 52 Week High
- DMAC $6.82
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- DMAC 65.09
- SLN 41.73
- Support Level
- DMAC $5.90
- SLN $4.91
- Resistance Level
- DMAC $6.18
- SLN $5.71
- Average True Range (ATR)
- DMAC 0.39
- SLN 0.51
- MACD
- DMAC 0.02
- SLN -0.04
- Stochastic Oscillator
- DMAC 79.10
- SLN 43.42
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.